How to buy United Therapeutics Corporation stock (UTHR)

United Therapeutics Corporation is a biotechnology business based in the US. United Therapeutics Corporation shares (UTHR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $360.16 – a decrease of 0.46% over the previous week. United Therapeutics Corporation employs 1,168 staff and has a trailing 12-month revenue of around $2.8 billion.

Our top picks for where to buy United Therapeutics Corporation stock

Buy United Therapeutics Corporation stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

United Therapeutics Corporation stock price (NASDAQ: UTHR)

Use our graph to track the performance of UTHR stocks over time.

United Therapeutics Corporation shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$360.16
52-week range	$208.62 - $417.82
50-day moving average more info button	$370.43
200-day moving average more info button	$314.46
Wall St. target price	$393.74
PE ratio more info button	15.7234
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$22.74

Is it a good time to buy United Therapeutics Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

United Therapeutics Corporation price performance over time

Historical closes compared with the close of $360.16 from 2024-12-19

1 week (2024-12-13)	-0.46%
1 month (2024-11-21)	-1.96%
3 months (2024-09-20)	2.03%
6 months (2024-06-20)	16.56%

1 year (2023-12-20)	59.71%
2 years (2022-12-20)	31.42%
3 years (2021-12-20)	78.10%
5 years (2019-12-20)	298.45%

Is United Therapeutics Corporation stock undervalued or overvalued?

Valuing United Therapeutics Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of United Therapeutics Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

United Therapeutics Corporation's P/E ratio

United Therapeutics Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, United Therapeutics Corporation shares trade at around 16x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

United Therapeutics Corporation's PEG ratio

United Therapeutics Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7741. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into United Therapeutics Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

United Therapeutics Corporation's EBITDA

United Therapeutics Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.4 billion.

The EBITDA is a measure of a United Therapeutics Corporation's overall financial performance and is widely used to measure a its profitability.

United Therapeutics Corporation financials

Revenue TTM	$2.8 billion
Operating margin TTM	54.51%
Gross profit TTM	$1.8 billion
Return on assets TTM	11.89%
Return on equity TTM	18.81%
Profit margin	40.31%
Book value	$136.74
Market Capitalization more info button	$16 billion

TTM: trailing 12 months

United Therapeutics Corporation's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like United Therapeutics Corporation.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

United Therapeutics Corporation's total ESG risk score

Total ESG risk: 35.51

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and United Therapeutics Corporation's overall score of 35.51 (as at 12/31/2018) is nothing to write home about – landing it in it in the 54th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like United Therapeutics Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

United Therapeutics Corporation's environmental score

Environmental score: 6.16/100

United Therapeutics Corporation's environmental score of 6.16 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that United Therapeutics Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

United Therapeutics Corporation's social score

Social score: 24.94/100

United Therapeutics Corporation's social score of 24.94 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that United Therapeutics Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

United Therapeutics Corporation's governance score

Governance score: 17.41/100

United Therapeutics Corporation's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that United Therapeutics Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

United Therapeutics Corporation's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. United Therapeutics Corporation scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that United Therapeutics Corporation has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

United Therapeutics Corporation was last rated for ESG on: 2019-01-01.

Total ESG score	35.51
Total ESG percentile	53.55
Environmental score	6.16
Environmental score percentile	9
Social score	24.94
Social score percentile	9
Governance score	17.41
Governance score percentile	9
Level of controversy	2

United Therapeutics Corporation share dividends

We're not expecting United Therapeutics Corporation to pay a dividend over the next 12 months.

Have United Therapeutics Corporation's shares ever split?

United Therapeutics Corporation's shares were split on a 2:1 basis on 22 September 2009 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your United Therapeutics Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for United Therapeutics Corporation shares which in turn could have impacted United Therapeutics Corporation's share price.

United Therapeutics Corporation share price volatility

Over the last 12 months, United Therapeutics Corporation's shares have ranged in value from as little as $208.6249 up to $417.815. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while United Therapeutics Corporation's is 0.561. This would suggest that United Therapeutics Corporation's shares are less volatile than average (for this exchange).

United Therapeutics Corporation overview

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag.

Frequently asked questions

What percentage of United Therapeutics Corporation is owned by insiders or institutions?
Currently 1.845% of United Therapeutics Corporation shares are held by insiders and 100.121% by institutions. How many people work for United Therapeutics Corporation?
Latest data suggests 1,168 work at United Therapeutics Corporation. When does the fiscal year end for United Therapeutics Corporation?
United Therapeutics Corporation's fiscal year ends in December. Where is United Therapeutics Corporation based?
United Therapeutics Corporation's address is: 1000 Spring Street, Silver Spring, MD, United States, 20910 What is United Therapeutics Corporation's ISIN number?
United Therapeutics Corporation's international securities identification number is: US91307C1027 What is United Therapeutics Corporation's CUSIP number?
United Therapeutics Corporation's Committee on Uniform Securities Identification Procedures number is: 91307C102